Literature DB >> 21396476

Symptomatic parainfluenza virus infections in children undergoing hematopoietic stem cell transplantation.

Ashok Srinivasan1, Chong Wang, Jie Yang, Jerry L Shenep, Wing H Leung, Randall T Hayden.   

Abstract

Parainfluenza virus (PIV) infections cause significant mortality in adults undergoing hematopoietic stem cell transplantation (HSCT). Children are more prone to PIV infections than adults; however, data on the epidemiology of these infections in children undergoing HSCT are limited. This study examined the incidence of symptomatic PIV infections, risk factors for lower respiratory tract infection (LRTI), and the impact on mortality after pediatric HSCT. A total of 1028 children who underwent HSCT between 1995 and 2009 were studied. PIV infections were detected in 46 of the 738 patients tested for respiratory infection (6.2%). PIV infection was the most common symptomatic respiratory viral infection in this population. On multivariate logistic regression analysis, receipt of an allogeneic transplant (P < .0001) and total body irradiation-based conditioning (P < .0001) were associated with increased risk of acquiring symptomatic PIV infection. Of the 46 HSCT patients with PIV infection, 18 (39%) had an LRTI. LRTI was associated with PIV infection in the first 100 days post-HSCT (P = .006), use of steroids (P = .035), and absolute leukocyte count (ALC) <100 cells/μL at the onset of infection (P < .0001). An ALC of <500 cells/μL was associated with prolonged viral shedding (P = .045). Six (13%) HSCT patients died of PIV infection. Mortality was associated with African-American ethnicity (P = .013), LRTI (P = .002), use of steroids (P < .0001), mechanical ventilation (P < .0001), and ALC <100 cells/μL at the onset of infection (P = .01). PIV infection causes significant morbidity and mortality in children undergoing HSCT.
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21396476      PMCID: PMC4936785          DOI: 10.1016/j.bbmt.2011.03.001

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  22 in total

1.  Survival and disinfection of parainfluenza viruses on environmental surfaces.

Authors:  M T Brady; J Evans; J Cuartas
Journal:  Am J Infect Control       Date:  1990-02       Impact factor: 2.918

2.  Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality.

Authors:  Suparno Chakrabarti; Irit Avivi; Stephen Mackinnon; Kate Ward; Panagiotis D Kottaridis; Husam Osman; H Waldmann; Geoff Hale; Christopher D Fegan; Kwee Yong; Anthony H Goldstone; David C Linch; Donald W Milligan
Journal:  Br J Haematol       Date:  2002-12       Impact factor: 6.998

3.  Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome.

Authors:  W G Nichols; L Corey; T Gooley; C Davis; M Boeckh
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

4.  Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old.

Authors:  G Reed; P H Jewett; J Thompson; S Tollefson; P F Wright
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

5.  Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment.

Authors:  J Elizaga; E Olavarria; J Apperley; J Goldman; K Ward
Journal:  Clin Infect Dis       Date:  2001-01-25       Impact factor: 9.079

6.  Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections.

Authors:  Julia L Hurwitz
Journal:  Pediatr Infect Dis J       Date:  2008-10       Impact factor: 2.129

7.  The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients.

Authors:  Adriana Weinberg; Martin R Zamora; Shaobing Li; Fernando Torres; Tony N Hodges
Journal:  J Clin Virol       Date:  2002-08       Impact factor: 3.168

8.  Patterns of shedding of myxoviruses and paramyxoviruses in children.

Authors:  A L Frank; L H Taber; C R Wells; J M Wells; W P Glezen; A Paredes
Journal:  J Infect Dis       Date:  1981-11       Impact factor: 5.226

9.  Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses.

Authors:  Veronique Erard; Jason W Chien; Hyung W Kim; W Garrett Nichols; Mary E Flowers; Paul J Martin; Lawrence Corey; Michael Boeckh
Journal:  J Infect Dis       Date:  2006-05-10       Impact factor: 5.226

10.  Polymerase chain reaction is more sensitive than viral culture and antigen testing for the detection of respiratory viruses in adults with hematological cancer and pneumonia.

Authors:  Leontine J R van Elden; Marian G J van Kraaij; Monique Nijhuis; Karin A W Hendriksen; Ad W Dekker; Maja Rozenberg-Arska; Anton M van Loon
Journal:  Clin Infect Dis       Date:  2001-12-04       Impact factor: 9.079

View more
  32 in total

1.  Premature activation of the paramyxovirus fusion protein before target cell attachment with corruption of the viral fusion machinery.

Authors:  Shohreh F Farzan; Laura M Palermo; Christine C Yokoyama; Gianmarco Orefice; Micaela Fornabaio; Aurijit Sarkar; Glen E Kellogg; Olga Greengard; Matteo Porotto; Anne Moscona
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

2.  Parainfluenza Virus 3-Specific T Cells: Opportunity for Intervention?

Authors:  Alpana Waghmare; Janet A Englund; Michael Boeckh
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

Review 3.  Pathogenesis of acute respiratory illness caused by human parainfluenza viruses.

Authors:  Henrick Schomacker; Anne Schaap-Nutt; Peter L Collins; Alexander C Schmidt
Journal:  Curr Opin Virol       Date:  2012-03-03       Impact factor: 7.090

4.  Dynamics of Sendai Virus Spread, Clearance, and Immunotherapeutic Efficacy after Hematopoietic Cell Transplant Imaged Noninvasively in Mice.

Authors:  Heba H Mostafa; Peter Vogel; Ashok Srinivasan; Charles J Russell
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

5.  Human rhinovirus C infections in pediatric hematology and oncology patients.

Authors:  Carolina Loria; Jennifer A Domm; Natasha B Halasa; Elizabeth Heitman; E Kathryn Miller; Meng Xu; Benjamin R Saville; Haydar Frangoul; John V Williams
Journal:  Pediatr Transplant       Date:  2014-11-06

6.  Risk Factors for Parainfluenza Virus Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation.

Authors:  Sachiko Seo; Hu Xie; Wendy M Leisenring; Jane M Kuypers; Farah T Sahoo; Sonia Goyal; Louise E Kimball; Angela P Campbell; Keith R Jerome; Janet A Englund; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2018-08-25       Impact factor: 5.742

7.  Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation.

Authors:  Ashok Srinivasan; Chong Wang; Deo K Srivastava; Ken Burnette; Jerry L Shenep; Wing Leung; Randall T Hayden
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-23       Impact factor: 5.742

8.  Circulating clinical strains of human parainfluenza virus reveal viral entry requirements for in vivo infection.

Authors:  Samantha G Palmer; Ilaria DeVito; Stephen G Jenkins; Stefan Niewiesk; Matteo Porotto; Anne Moscona
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

Review 9.  Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.

Authors:  Charles J Russell; Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2015-12-09       Impact factor: 5.217

10.  Parainfluenza virus type 3 Ab in allogeneic hematopoietic cell transplant recipients: factors influencing post-transplant Ab titers and associated outcomes.

Authors:  S Seo; H Xie; R A Karron; B Thumar; J A Englund; W M Leisenring; T Stevens-Ayers; M Boeckh; A P Campbell
Journal:  Bone Marrow Transplant       Date:  2014-06-30       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.